260 related articles for article (PubMed ID: 17998055)
1. Control of erythropoietin gene expression and its use in medicine.
Jelkmann W
Methods Enzymol; 2007; 435():179-97. PubMed ID: 17998055
[TBL] [Abstract][Full Text] [Related]
2. Suppression of erythropoietin gene expression by cadmium depends on inhibition of HIF-1, not stimulation of GATA-2.
Obara N; Imagawa S; Nakano Y; Suzuki N; Yamamoto M; Nagasawa T
Arch Toxicol; 2003 May; 77(5):267-73. PubMed ID: 12734640
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin production: Molecular mechanisms of the antagonistic actions of cyclic adenosine monophosphate and interleukin-1.
Batmunkh C; Krajewski J; Jelkmann W; Hellwig-Bürgel T
FEBS Lett; 2006 May; 580(13):3153-60. PubMed ID: 16684536
[TBL] [Abstract][Full Text] [Related]
4. Use of gene-manipulated mice in the study of erythropoietin gene expression.
Suzuki N; Obara N; Yamamoto M
Methods Enzymol; 2007; 435():157-77. PubMed ID: 17998054
[TBL] [Abstract][Full Text] [Related]
5. Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin delta, Dynepo).
Llop E; Gutiérrez-Gallego R; Segura J; Mallorquí J; Pascual JA
Anal Biochem; 2008 Dec; 383(2):243-54. PubMed ID: 18804089
[TBL] [Abstract][Full Text] [Related]
6. Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies.
Kokhaei P; Abdalla AO; Hansson L; Mikaelsson E; Kubbies M; Haselbeck A; Jernberg-Wiklund H; Mellstedt H; Osterborg A
Clin Cancer Res; 2007 Jun; 13(12):3536-44. PubMed ID: 17575216
[TBL] [Abstract][Full Text] [Related]
7. Erythropoiesis stimulating agents and techniques: a challenge for doping analysts.
Jelkmann W
Curr Med Chem; 2009; 16(10):1236-47. PubMed ID: 19355882
[TBL] [Abstract][Full Text] [Related]
8. Chronic kidney disease-associated anemia: new remedies.
Del Vecchio L; Cavalli A; Tucci B; Locatelli F
Curr Opin Investig Drugs; 2010 Sep; 11(9):1030-8. PubMed ID: 20730698
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in erythropoietic agents in renal anemia.
Macdougall IC
Semin Nephrol; 2006 Jul; 26(4):313-8. PubMed ID: 16949470
[TBL] [Abstract][Full Text] [Related]
10. [The study on in vivo erythropoietin gene transfer for treatment of renal anemia in animal model].
Sui B; Han F; Wu S
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Jun; 12(2):161-4. PubMed ID: 12515198
[TBL] [Abstract][Full Text] [Related]
11. Delivering erythropoietin through genetically engineered cells.
Bohl D; Heard JM
J Am Soc Nephrol; 2000 Nov; 11 Suppl 16():S159-62. PubMed ID: 11065350
[TBL] [Abstract][Full Text] [Related]
12. A hypoxia-inducible gene expression system using erythropoietin 3' untranslated region for the gene therapy of rat spinal cord injury.
Choi BH; Ha Y; Ahn CH; Huang X; Kim JM; Park SR; Park H; Park HC; Kim SW; Lee M
Neurosci Lett; 2007 Jan; 412(2):118-22. PubMed ID: 17178192
[TBL] [Abstract][Full Text] [Related]
13. The biology and clinical applications of recombinant erythropoietin.
Spivak JL
Semin Oncol; 1998 Jun; 25(3 Suppl 7):7-11. PubMed ID: 9671323
[TBL] [Abstract][Full Text] [Related]
14. High-level expression of secreted complex glycosylated recombinant human erythropoietin in the Physcomitrella Delta-fuc-t Delta-xyl-t mutant.
Weise A; Altmann F; Rodriguez-Franco M; Sjoberg ER; Bäumer W; Launhardt H; Kietzmann M; Gorr G
Plant Biotechnol J; 2007 May; 5(3):389-401. PubMed ID: 17359496
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure.
Teixeira AM; Garrido P; Santos P; Alves R; Parada B; Costa E; Almeida A; Teixeira-Lemos E; Sereno J; Pinto R; Belo L; Santos-Silva A; Teixeira F; Reis F
Ren Fail; 2010; 32(9):1073-80. PubMed ID: 20863212
[TBL] [Abstract][Full Text] [Related]
16. A mouse model for an erythropoietin-deficiency anemia.
Zeigler BM; Vajdos J; Qin W; Loverro L; Niss K
Dis Model Mech; 2010; 3(11-12):763-72. PubMed ID: 20959632
[TBL] [Abstract][Full Text] [Related]
17. Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts.
Régulier E; Schneider BL; Déglon N; Beuzard Y; Aebischer P
Gene Ther; 1998 Aug; 5(8):1014-22. PubMed ID: 10326023
[TBL] [Abstract][Full Text] [Related]
18. Importance of biologic follow-ons: experience with EPO.
Casadevall N; Rossert J
Best Pract Res Clin Haematol; 2005; 18(3):381-7. PubMed ID: 15792912
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the erythropoietin gene.
Blanchard KL; Fandrey J; Goldberg MA; Bunn HF
Stem Cells; 1993 May; 11 Suppl 1():1-7. PubMed ID: 8318914
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation.
Buck I; Morceau F; Cristofanon S; Heintz C; Chateauvieux S; Reuter S; Dicato M; Diederich M
Biochem Pharmacol; 2008 Nov; 76(10):1229-39. PubMed ID: 18805401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
